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Pulmonary microbiology of HIV positive subjects with
community-acquired pneumonia (CAP) with special
emphasis on Mycoplasma pneumoniae
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S. Solomon3
1 Raga’s Dental College, 600119, India
2 University of Madras, Chennai, India
3 YRG CARE, Chennai, India
Background: A great deal of effort has been devoted to
understanding the role of AIDSassociated mycoplasmas in
recent years. However, the role of Mycoplasma pneumoniae
in HIV disease remains unclear.
Methods: We studied 300 adult HIV infected persons (200
with community-acquired pneumonia (CAP) and 100 with no
respiratory illness) and 75 HIV uninfected persons with CAP
and analysed the prevalence of respiratory pathogens.
Results: Prevalence of M. pneumoniae was 17% by
induced sputum and 11.3% by throat swab culture in HIV
positive subjects. Seroprevalence of anti-M. pneumoniae
IgM was 11.7% by ELISA and 14.3% by gelatin microparti-
cle agglutination test. Prevalence of M. pneumoniae among
HIV negative cases was relatively low. Streptococcus pneu-
moniaewas predominant (28%) among subjects with lower
respiratory disease, whereas Staphylococcus aureus (15%)
was more common among cases with upper respiratory
illness. Rales (P=0.001), pharyngeal erythema (P=0.02),
cervical adenopathy (P=0.004) and crepitations (P=0.001)
showed signiﬁcance in relation to M. pneumoniae positiv-
ity. Statistical signiﬁcance was observed with regard to total
lymphocyte count (P=0.02) and erythrocyte sedimentation
rate (P=0.04), and M. pneumoniae positivity.
Conclusion: The prevalence of M. pneumoniae in HIV
infected subjects was relatively higher than HIV uninfected
subjects with respiratory disease.
doi:10.1016/j.ijid.2010.02.511
78.006
Kaposi’s sarcoma (KS) and AIDS. Survival study
D.B. Lima1,∗, A. Barbosa2, E.F. Cunha1, R.G. Cunha1, J.P.
Almeida1, V.R. Gomes1
1 Infectious Diseases Unit at University Hospital Pedro
Ernesto, Faculty of Medical Sciences, State University of
Rio de Janeiro /UERJ — RJ, Brazil., Rio de Janeiro, Brazil
2 University Hospital Pedro Ernesto, Rio de Janeiro State
University- UERJ, Brazil., Rio de Janeiro, Rio de Janeiro,
Brazil
Background: To evaluate the factors associated with sur-
vival time of AIDS patients with KS.
Methods: We studied the medical records of patients with
AIDS / KS, adults of both sexes admitted for clinical follow-
up at the Infectious Disease Unit from 1985 to 2008. We used
a protocol with demographic data, CD4 cell count, extension
of the lesion (localized or disseminated) and survival time
of each patient. The EPI-INFO 3.4.3 was used to analyse the
results.
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Results: Among 136 patients with AIDS and cancer
e found anal carcinoma 4(2.9%) Hodgkin’s lymphoma 7
5.1%),non-Hodgkin’s lymphoma 26 (19.1%), KS 90 (66.2%),
ther 9 (6.6%). Among the cases of KS, 86 men and 4
omen, disseminated disease 62 (68.9%), 3 women (4.8%),
9 men (95.2%); localized 28 (31.1%), 1 woman (3.6%), 27
en (96.4%). Average age of 37.27 ± 9.09 SK, localized
8.92 ± 10.06, disseminated 36.5 ± 8.59 ANOVA p=0.25.
edian CD4 localized 315 cells/mm+ (27-1088), dissemi-
ated 297 cells/mm+ (11-778) Kruskal-Wallis p=0.41, no
tatistical difference. Survival time of KS total median 304
ays (0-4090), localized median 270 (0-4090), disseminated
30 (10.0-3105) Kruskal-Wallis p=0.96, no statistical differ-
nce. The median survival time of those on antiretroviral
reatment was 721 days (0.0-4090) and without antiretrovi-
al treatment 120 days (2.0-2555) Kruskal-Wallis p=0.0000.
Conclusion: The use of antiretrovirals drugs was the only
eterminant of improved survival time among patients with
IDS and KS.
oi:10.1016/j.ijid.2010.02.512
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Background: HIV-related central nervous system (CNS)
isorders and infections represent substantial personal, eco-
omic, and societal problems. However, its understanding is
till lacking in areas of some developing countries where HIV
rograms are still limited.
Methods: Herein we describe epidemiology, clinical fea-
ures and diagnosis of opportunistic infections in CNS and
ssociated neurologic disorders in HIV infected patients in a
estern hospital of Venezuela, January 2007 to September
009. Monthly records of conﬁrmed HIV cases from the epi-
emiological archives were collected. All the patients with
pportunistic infections in CNS or associated neurologic dis-
rders were selected. All the clinical relevant variables were
onsidered in this analysis.
Results: A total of 228 patients with HIV infection were
reated during the study period; thirteen of them (5%)
resented neuropathology. Twelve (92%) were male, mean
ge was 35 years-old, previous HIV was diagnosed in nine
atients (69%) with a mean of 9 months, just 4 (30%) were
eceiving antiretroviral treatment. The most common pre-
ented symptom was fever 6/13 (46%), followed by muscular
trength loss and headache 5/13 (38%), convulsions and con-
cience alteration also had an important incidence 4/13
30%) among other ﬁndings. Neurological diagnoses were:
/13 (53%) Cerebral Toxoplasmosis, 3/13 (23%) Central ner-
ous system Cryptococcus neoformans infection, 2/13 (15%)
erebral Tuberculosis and 1/13 motor-sensitive neuropathy
